Novartis terminates Fabhalta mid-stage trial in lupus nephritis
Novartis has ended a mid-stage clinical trial testing Fabhalta in patients with lupus nephritis, citing 'strategic considerations' according to federal clinical trial records.
2 sourcesClinical trials
00